Alexander J. Muller
Affiliations: | Biochemistry | Drexel University College of Medicine, Philadelphia, PA, United States |
Area:
Pharmacology, Oncology, Molecular BiologyGoogle:
"Alexander Muller"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shen SC, Dey S, DuHadaway JB, et al. (2025) Neovascular pruning by IDO1 inhibitors can potentiate immunogenic cytotoxicity of ischemia-targeted agents to synergistically enhance anti-PD-1 responsiveness. Journal For Immunotherapy of Cancer. 13 |
| Muller AJ, Mondal A, Dey S, et al. (2023) IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation. Frontiers in Oncology. 13: 1165298 |
| Muller AJ, Thomas S, Prendergast GC. (2023) A Brief Overview of Cancer Vaccines. Cancer Journal (Sudbury, Mass.). 29: 34-37 |
| Merlo LMF, Peng W, DuHadaway JB, et al. (2022) The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. Journal of Immunology (Baltimore, Md. : 1950). 208: 571-581 |
| Dey S, Mondal A, DuHadaway JB, et al. (2021) IDO1 Signaling Through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization. Cancer Immunology Research |
| Merlo LMF, DuHadaway JB, Montgomery JD, et al. (2020) Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Frontiers in Immunology. 11: 1861 |
| Dey S, Sutanto-Ward E, Kopp KL, et al. (2020) Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 and CD4 T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. Journal For Immunotherapy of Cancer. 8 |
| Dey S, Mondal A, DuHadaway JB, et al. (2020) Abstract 1474: IDO1 signaling supports inflammatory neovascularization Cancer Research. 80: 1474-1474 |
| Prendergast GC, Nevler A, Muller AJ, et al. (2019) Abstract A101: IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma Cancer Immunology Research. 7 |
| Winters M, DuHadaway JB, Pham KN, et al. (2018) Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. European Journal of Medicinal Chemistry. 162: 455-464 |